Devicare and nine leading Spanish hospitals in urology have successfully completed the clinical trial which demonstrates the efficacy of the combined use of a medical device (Lit-Control® pH Meter) and a nutraceutical (Lit-Control® pH Down) to prevent the encrustation of double J catheters by monitoring urinary pH and supplying phytates (crystallisation inhibitors).

The results of this pioneering study at the international level will be presented in the Meeting of the Spanish Association of Urology in January in Palma de Mallorca and in the European Association of Urology Congress in March in Barcelona in front of more than 10,000 urologists. The solution provides a response to an unresolved medical need which affects an important part of the patients affected by urolithiasis.

In the words of Dr Jordi Cuñé, Medical Director of this firm member of CataloniaBio & HealthTech, this trial is considered “a resounding success as it validates the working hypothesis and reinforces our firm commitment to providing innovative solutions in the field of urology”.

This week Devicare participates at the J.P. Morgan Healthcare Conference in San Francisco.

More information

Photo: From left to right, Jordi Cuñé, Medical Director at Devicare, and Xavier Peris, Sales and Marketing Director - © Devicare